Matthew Pratt Whalen Buys Shares of MIRA Pharmaceuticals
Matthew Pratt Whalen purchased 50,000 shares of MIRA Pharmaceuticals on June 12, 2026.
Key Points
- Matthew Pratt Whalen acquired 50,000 shares of MIRA Pharmaceuticals, Inc. on June 12, 2026.
- MIRA Pharmaceuticals, Inc. trades around $0.93 with a market cap of approximately $39.2 million.
- Other insiders, including CEO Erez Aminov, have also made significant share purchases in recent months.
On June 12, 2026, Matthew Pratt Whalen bought 50,000 shares of MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA). This insider transaction occurred at a time when the stock was trading near $0.93 per share.
Insider Buying and Selling at MIRA Pharmaceuticals, Inc.
Matthew Pratt Whalen wasn't the only insider buying shares. On the same day, Edward Clouston Macpherson, Matthew Paul Del Giudice, and Denil Nanji Shekhat each purchased 50,000 shares. Earlier, on December 17, 2025, CEO and Chairman Erez Aminov made a notable acquisition of 3,155,170 shares.
Other Institutional Activity in MIRA Pharmaceuticals
Several institutional investors have also adjusted their positions in MIRA Pharmaceuticals. Vanguard Capital Management LLC added 693,912 shares, bringing its total to 693,912 shares valued at approximately $742,486. Geode Capital Management, LLC increased its stake by 18,012 shares, ending with 290,890 shares worth about $311,251. Meanwhile, Suncoast Equity Management reduced its holdings by 12,644 shares, resulting in 90,645 shares valued at $96,990.
MIRA Pharmaceuticals Stock Snapshot
Shares of MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) are trading near $0.93. The company has a market cap of approximately $39.2 million. It is not currently profitable, which means it has no meaningful P/E ratio. The stock's 52-week range is between $0.90 and $2.45. MIRA Pharmaceuticals has a strong liquidity position, with a current ratio of 82.16 and a quick ratio of 81.97.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc. is a healthcare company based in Miami, Florida. It focuses on developing treatments for neurologic and neuropsychiatric disorders. The company holds exclusive rights to Ketamir-2, an NMDA receptor modulator that has completed a Phase 1 clinical trial. Additionally, MIRA is developing MIRA-55 for anxiety and cognitive decline and SKNY-1 for obesity and nicotine dependence. The company was founded in 2020 and is led by CEO Erez Aminov.
Bottom Line
Insider purchases like those by Matthew Pratt Whalen and other executives can attract attention from investors looking for signals of confidence in the company. MIRA Pharmaceuticals operates in the healthcare sector, focusing on innovative treatments for neurological conditions. The insider transactions reflect activity up to June 12, 2026, and provide a backward-looking view of executive sentiment.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.